Flowonix Medical Inc. and Cerebral Therapeutics, LLC Announce Exclusive Agreement for Drug Delivery to Brain

MOUNT OLIVE, N.J., Oct. 21, 2015 /PRNewswire/ -- Flowonix Medical Inc. of New Jersey and Colorado-based Cerebral Therapeutics, LLC announced today that they have entered into an exclusive agreement to develop a unique implanted drug delivery system which provides direct infusion of a therapeutic drug into targeted areas of the brain for treatment of neurological diseases.  By delivering microdoses of medication directly to the brain, this system will be able to bypass the blood-brain barrier and deliver the medication to a specific targeted region.

"Neurological disorders can be devastating to patients and their families, and patients are often left with few options," stated Steven Adler, President and CEO of Flowonix Medical Inc. "Flowonix has long been a world leader in implantable infusion systems and we have specific expertise in the accurate and reliable delivery of microdoses of medication. We are pleased to partner with Cerebral Therapeutics to bring this safe, effective, and successful drug delivery technology to one of the most challenging frontiers in medicine—the brain."

"The combination of small-molecule therapy with established infusion pump delivery could be a treatment alternative with profoundly positive ramifications," stated Dr. Ashwini Sharan, Neurosurgical and Neurological Professor at Jefferson University, and President-Elect for the North American Neuromodulation Society (NANS). "The use of implantable infusion pumps to deliver novel therapeutic agents holds great promise."

"Cerebral Therapeutics chose to work with Flowonix because the Prometra® and Prometra® II infusion pumps offer a patented valve-gated drug delivery system which allows for very precise dosing of medicine," stated Dr. Dan Abrams, CEO of Cerebral Therapeutics. "The state-of-the-art Prometra pump platform will be used to deliver medication directly to the brain. For certain agents, this may reduce the doses necessary for therapeutic effect, lessen the risk of systemic toxicity, and possibly ameliorate the side effects associated with certain types of neurological therapies."

The new agreement will allow Cerebral Therapeutics, LLC and Flowonix Medical Inc. to develop drug-pump combination products aimed at addressing unmet needs in neurological therapies.

"Clinical trials will be needed to ascertain how targeted delivery of drugs directly to the brain may benefit neurological patients," continued Dr. Dan Abrams. "Experience with intraspinal drug therapy demonstrates the many advantages of controlled and targeted drug therapy. We look forward to working with Flowonix because of their state of the art technology, commitment to developing new therapies, and leadership in infusion pump devices."

Steve Adler continued, "This is an important partnership for Flowonix, which already has the privilege of being a leader in bringing infusion pump technology to address the largely unmet need of chronic pain. It demonstrates our commitment at Flowonix to bringing the most advanced technology to our physicians when treating their most challenging patients, particularly those with neurological conditions and with few other treatment options."

About Flowonix
Flowonix Medical Inc. (www.flowonix.com) headquartered in Mt. Olive, NJ, is dedicated to working with healthcare professionals to help ease suffering associated with chronic pain and allow patients to reclaim their lives through innovation and therapy advancements. The strategic business goal of Flowonix Medical Inc. is to become the leading implantable drug delivery company in the world.  Founded in 2005, Flowonix Medical Inc. received approval to conduct its first clinical trial in 2007 on the Prometra programmable implantable pump. The company received approval by the FDA to market the Prometra in 2012. Flowonix Medical Inc. has been granted multiple patents and is focused on working closely with physicians to rapidly improve the capabilities of implantable drug delivery and management systems.
For more information, please visit http://www.flowonix.com.  

About Cerebral Therapeutics

Cerebral Therapeutics, LLC (www.cerebraltherapeutics.com) is a privately-held company founded with the goal of addressing the well-recognized limitations of existing treatments for uncontrolled neurological diseases.  Cerebral Therapeutics is combining advanced micro-dosing technology with proprietary medications to precisely deliver treatments to the other side of the blood-brain barrier to improve the lives of patients with uncontrolled neurological disease.    With a promising route of administration, Cerebral Therapeutics offers a new approach to managing neurological diseases by means of delivering ideal dosing to targeted sites within the brain.  Initially, Cerebral Therapeutics is focused on improving outcomes for patients with refractory epilepsy by targeting the site of the seizure generation and propagation in the brain.   Future cerebral therapeutic areas include obesity, Alzheimer's disease, Parkinson's disease, anxiety spectrum disorder, and brain cancer.

Logo - http://photos.prnewswire.com/prnh/20150627/226378LOGO

SOURCE Flowonix Medical Inc.

Related Links

http://www.flowonix.com